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The aim of this study was to design a controlled release vehicle for insulin to preserve its stability and 
biological activity during fabrication and release. A modiﬁed, double emulsion, solvent evaporation, 
technique using homogenisation force optimised entrapment efﬁciency of insulin into biodegradable 
nanoparticles (NP) prepared from poly (DL-lactic-co-glycolic acid) (PLGA) and its PEGylated diblock 
copolymers. Formulation parameters (type of polymer and its concentration, stabiliser concentration and 
volume of internal aqueous phase) and physicochemical characteristics (size, zeta potential, 
encapsulation efﬁciency, in vitro release proﬁles and in vitro stability) were investigated. In vivo insulin 
sensitivity was tested by diet-induced type II diabetic mice. Bioactivity of insulin was studied using Swiss 
TO mice with streptozotocin-induced type I diabetic proﬁle. Insulin-loaded NP were spherical and 
negatively charged with an average diameter of 200–400 nm. Insulin encapsulation efﬁciency increased 
signiﬁcantly with increasing ratio of co-polymeric PEG. The internal aqueous phase volume had a 
signiﬁcant impact on encapsulation efﬁciency, initial burst release and NP size. Optimised insulin NP 
formulated from 10% PEG–PLGA retained insulin integrity in vitro, insulin sensitivity in vivo and induced a 
sustained hypoglycaemic effect from 3 h to 6 days in type I diabetic mice. 
. 
 
 
 
1. Introduction 
 
Diabetes is a common cause of morbidity and mortality, 
afﬂicting about 30 million children and adults in the United States 
alone (King et al., 1998). Maintaining strict glycaemic control with 
insulin administration is a vital treatment option for both type I 
and type II diabetic patients (UKPDS, 1998). Type I diabetes, is 
characterized by an absolute deﬁciency of insulin however the 
majority of diabetic patients have type II disease, which is 
characterized by reduced sensitivity of cells to insulin action 
beside a relatively insulin deﬁciency (Steil, 1999). 
Various novel insulin delivery approaches have been described, 
but  parenteral  subcutaneous  injection  is  still  the  mainstay 
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. 
(Agarwal and Khan, 2001). Novel approaches include use of 
polymeric NP (Richardson et al., 2001) and the careful choice of the 
encapsulating polymer provides a biodegradable and biocompati- 
ble formulation (Mundargi et al., 2008). Biodegradable polyesters 
are ideal precursors for making NP that encapsulate smaller 
peptides and proteins, leading to improved pharmacokinetic 
proﬁles and reduced frequency of administration (Chan et al., 
2009), but they are not without difﬁculty (Takenaga et al., 2002). 
The major problem is the inherent instability of therapeutic 
proteins when exposed to the harsh formulation conditions 
prevailing during conventional emulsion/solvent removal techni- 
ques (Sah, 1999). Conformational instability results in incomplete 
release from the matrix (Lu and Park, 1995). Other difﬁculties 
include a high initial burst release of drug and low encapsulation 
efﬁciencies (Yeo and Park, 2004). Further limitations arise due to 
the innate polyester hydrophobicity. Insertion of poly (ethylene 
glycol) (PEG) into the polymeric structure, as a block copolymer, is 
a  simple  way  to  alleviate  this  problem,  spawning  various 
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Fig. 1. Sequence of NP manufacturing steps involving formation of primary and 
secondary emulsions. The experimental factors changed in the study comprised 
variation in internal aqueous phase volume, polymer type, polymer concentration 
and PVA concentration. 
 
 
formulations, such as NP, hydrogels, micelles and injectable 
systems possessing more favourable pharmacokinetic parameters 
(Jeong et al., 1997). 
The double emulsion technique is used frequently to process 
PLGA–PEG block copolymers, producing practical yields and more 
efﬁcient peptide and protein encapsulation than other methods. It 
involves dissolution of peptide in an aqueous medium, followed by 
either sonication-assisted dispersal or homogenisation into an 
immiscible organic polymer solution. This primary emulsion is 
then transferred into an aqueous medium containing a stabiliser, 
which creates a secondary emulsion, again assisted by either 
sonication or homogenisation. Residual organic solvent can be 
removed by heat and vacuum (Li et al., 2001). 
Protein microencapsulation using this methodology reveals 
that the emulsiﬁcation step is potentially detrimental to the 
biological activity of the incorporated protein (Li et al., 2000). 
Upon homogenisation of aqueous protein solutions with 
dichloromethane, for example, shear stress facilitates the 
formation of insoluble protein aggregates at the aqueous-organic 
interface of the primary emulsion (Diwan and Park, 2001). 
Alternatively, the use of sonication as the source of agitation to 
form the two emulsion types preserves the physical and chemical 
stability of insulin during NP fabrication (Fonte et al., 2012; 
Sarmento et al., 2007; Sheshala et al., 2009). However, low 
encapsulation efﬁciency (Sarmento et al., 2007; Sheshala et al., 
2009) and high initial burst effect (Fonte et al., 2012; Ibrahim 
et al., 2005) are observed. 
Recently, it is reported that the double emulsion based 
technologies are widely used for the preparation of micro/ 
nanoparticles of various classes of substances that are pharma- 
ceutically and biopharmaceutically active. Examples include, but 
are not limited to Leuprolide, Hepatitis B surface antigen, 
Recombinant human erythropoietin (rhEPO), Tetanus toxoid, 
Leutinizing hormone releasing hormone (LHRH) antagonist, and 
Exenatide, all of which exhibited biological activity following in 
vivo administration (Giri et al., 2013). 
It has been observed that the inclusion of PEG segments in 
PLGA polymers played an important role on the properties of 
micro/nanoparticles. Diblock copolymer PLA-mPEG yielded a 
more stable interfacial layer at the interface of oil and water phase 
compared to PLGA, and thus was more suitable  to stabilize 
primary emulsion and protect coalescence of inner droplets and 
external water phase, resulting in high encapsulation efﬁciency 
and stability (Wei et al., 2008). 
PLGA microspheres containing peptide and protein drugs and 
already being marketed is limited to parenteral delivery of 
leuprolide  (LHRH)  analogues,  human  growth  hormone  and 
 
 
 
Table 1 
Formulation identiﬁcation and parameters used to produce insulin NP. 
 
Formulation ID Polymer type Polymer conc. 
(%w/v) 
PVA conc. 
(%w/v) 
Internal aqueous phase volume (ml) 
F1 PLGA 2.5 1.25 0.50 
F2 PLGA 2.5 2.50 0.50 
F3 PLGA 2.5 5.00 0.50 
F4 5%  PEG–PLGA 2.5 1.25 0.50 
F5 5%  PEG–PLGA 2.5 2.50 0.50 
F6 5%  PEG–PLGA 2.5 5.00 0.50 
F7 10% PEG–PLGA 2.5 1.25 0.50 
F8 10% PEG–PLGA 2.5 2.50 0.50 
F9 10% PEG–PLGA 2.5 5.00 0.50 
F10 PLGA 5.0 1.25 0.50 
F11 PLGA 7.5 1.25 0.50 
F12 5%  PEG–PLGA 5.0 1.25 0.50 
F13 5%  PEG–PLGA 7.5 1.25 0.50 
F14 10% PEG–PLGA 5.0 1.25 0.50 
F15 10% PEG–PLGA 7.5 1.25 0.50 
F16 PLGA 2.5 1.25 0.20 
F17 PLGA 2.5 1.25 0.75 
F18 5%  PEG–PLGA 2.5 1.25 0.20 
F19 5%  PEG–PLGA 2.5 1.25 0.75 
F20 10% PEG–PLGA 2.5 1.25 0.20 
F21 10% PEG–PLGA 2.5 1.25 0.75 
F22 10% PEG–PLGA 5.0 1.25 0.20 
F23 10% PEG–PLGA 7.5 1.25 0.20 
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Fig. 2.  Effects of polymer type on insulin nanoparticle size (A), zeta potential (B), encapsulation efﬁciency (C) and insulin in vitro release (D). Values are mean ± SEM with n = 3. 
For 2A–2C, *P < 0.05, **P < 0.01, ***P < 0.001 compared with PLGA. 
D
P < 0.05 compared with 5% PEG–PLGA. 
 
 
octreotide acetate peptide which were formulated using double 
emulsion technique (Almeida and Souto, 2007). 
The formulation plan used in this study was based on a 
modiﬁed double emulsion solvent evaporation technique, using 
homogenisation to optimise the entrapment efﬁciency of insulin 
and to modify its initial burst from biodegradable NP prepared 
from PLGA and diblock copolymer variants containing PEG. The 
inﬂuence of various formulation parameters, such as the polymer 
type, its concentration, stabiliser concentration and volume of 
internal aqueous phase on the physicochemical characteristics of 
the NP, in vitro release proﬁles, in vitro stability, in vivo sensitivity 
and bioactivity of encapsulated insulin were investigated. Here, we 
show that an optimised fabrication method was developed to 
prepare a stable long-acting insulin NP formulation providing basal 
insulin delivery requirement via a single weekly subcutaneous 
injection. 
 
2. Materials and methods 
 
2.1. Materials 
 
PLGA (Resomer1 RG 503H) with a lactic:glycolic ratio of 50:50 
(MW 34 kDa) and block copolymers of poly[(D,L-lactide-co- 
glycolide)-co-PEG] (Resomer1 RGP d 5055 (5% PEG, 5 kDa) and 
Resomer1 RGP d 50105 (10% PEG, 5 kDa)) were purchased from 
Boehringer-Ingelheim Ltd. (Ingelheim, Germany). Bovine insulin 
(51 amino acids, MW 5734 Da), poly (vinyl alcohol) (PVA, 87–89% 
hydrolysed, MW 31,000–50,000) and phosphate buffered saline 
(PBS) were obtained from Sigma Chemical Co. (St. Louis, USA). 
MicroBCA Kit was obtained from Pierce (Rockford, IL). Dichloro- 
methane was of HPLC grade and other reagents were of analytical 
grade or higher. All water used in this study was produced to type 
1 standard (Milli-Q1, 18.2 MV cm at 25 o C). 
 
2.2. Preparation of insulin-loaded NP 
 
The modiﬁed, double emulsion, solvent evaporation method 
used in this work is shown in Fig. 1. Insulin (2.0 mg) was dissolved 
in 0.1 M HCl to form the internal aqueous phase and mixed with 
2.0 ml of dichloromethane (DCM) containing different polymers 
and emulsiﬁed (Silverson L5T Homogeniser, Silverson Machines, 
England) at 6000 rpm for 2 min. The ﬁrst emulsion (W1/O) was 
injected directly into 50 ml poly (vinyl alcohol) (PVA) solution 
under agitation  and  emulsiﬁcation  continued  at  10,000 rpm  for 
6 min to produce a W1/O/W2 emulsion using the same homog- 
eniser. The system was stirred (24 h) under vacuum to evaporate 
DCM and prevent pore formation on the surface of the NP. Once 
formed, NP were centrifuged at 10,000 rpm for 30 min at 4 o C using 
centrifugation (Sigma 3-30K, Germany), washed three times with 
distilled water and 2% w/v sucrose solution and freeze dried 
(LABCONCO, Kansas city, Missouri, 64132, USA). The ﬁnal product 
was stored in a desiccator at room temperature. 
 
2.3. NP characterisation 
 
2.3.1. Particle size, zeta potential and surface analyses 
Lyophilised NP samples (5.0 mg) were diluted with Milli-Q- 
water to a suitable concentration and suspended with vortex for 
5 min. The mean diameter and size distribution were analysed by 
photon correlation spectroscopy (PCS) using a Malvern Zetasizer 
5000 (Malvern Instruments, UK). All measurements were per- 
formed in triplicate. 
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Fig. 3. Effects of PVA concentration in the external aqueous phase on insulin nanoparticle size (A), zeta potential (B), encapsulation efﬁciency (C) and insulin in vitro release 
(D). Values are mean ± SEM with n = 3. For 3A–3C, *P < 0.05, **P < 0.01, ***P < 0.001  compared  with  1.25%  PVA  for  each  polymer  type.  
D
P < 0.05,  
DD
P < 0.01, 
DDDD
P < 0.001 compared with 2.5% PVA for each polymer type. 
 
 
 
Zeta  potential  analysis  was  performed  on  lyophilised  NP 
samples following dilution and adjustment of conductivity using 
0.001 M KCl. Electrophoretic mobility was measured using laser 
doppler anemometry (Malvern Zetasizer 5000, Malvern Instru- 
ments, UK). All measurements were performed in triplicate. 
Surface morphology was studied using scanning electron micros- 
copy (FEI Quanta 400 FEG SEM) following coating with a gold layer 
under vacuum. 
 
2.3.2. Determination of insulin loading and encapsulation efﬁciency 
Insulin content was determined by both direct extraction from 
intact NP and by an indirect procedure based on determination of 
non-encapsulated insulin. The direct method began by dissolving 
NP of known mass into 0.5 ml of 1 M sodium hydroxide and 
incubating overnight at 37 o C. The solution was then neutralised 
(1 M HCl), centrifuged for 5 min at 10,000 rpm and the supernatant 
analysed  for  total  protein  content  using  bicinchoninic  acid 
detection of copper reduction (MicroBCA protein assay kit) (Carino 
et al., 2000). From this result, the percentage loading (w/w, insulin 
content per unit mass of dry NP) was determined. Encapsulation 
efﬁciency was expressed as a ratio of actual insulin loading to the 
theoretical loading. The indirect method was based on determin- 
ing non-encapsulated free insulin content in the supernatant using 
radioimmunoassay(Flatt and Bailey, 1981). The concentrations of 
insulin in unknown samples were extrapolated using a standard 
curve of bovine insulin prepared over a concentration range of 
3.9 x 10-3 to 20.0 ng ml-1. Encapsulation in the NP was calculated 
by the difference between the initial amount of insulin added and 
the non-entrapped insulin remaining in the external phase after 
NP formation. Each sample was assayed in triplicate and the 
average of the two assay method results was represented as the % 
insulin encapsulation efﬁciency. 
 
 
2.4. In vitro release studies 
 
Insulin-loaded NP (5.0 mg) were dispersed in 1.0 ml of 
phosphate buffered saline (PBS, pH 7.4) solution and incubated 
at 37 o C using a reciprocal shaking water bath at 100 rpm. Samples 
were taken at predetermined time intervals of 1, 12, 24, 48, 72, 96, 
120, 144 and 168 h and replaced with fresh medium maintained at 
the same temperature. Samples were centrifuged for 5 min at 
10,000 rpm and the insulin content in the supernatant determined 
in triplicate by direct analysis and radioimmunoassay, as described 
previously in Section 2.3. 
 
 
2.5. In vitro stability studies 
 
SDS-PAGE analysis was performed using a BioRad Mini Protean 
II gel apparatus (Hercules, CA). Sampling was performed on the 
receiver phase of the in vitro release experiment. The sample was 
prepared under non-reducing conditions for application on a gel 
consisting of 4% and 12% stacking and resolving gel, respectively. 
Coomassie brilliant blue ﬁxative solution was employed to reveal 
the separated protein bands. Insulin dispersed in PBS was used as 
control.  Electrophoresis  was  run  in  constant  current  mode  of 
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Fig. 4. Effects of polymer concentration on insulin nanoparticle size (A), zeta potential (B), encapsulation efﬁciency (C) and insulin in vitro release (D). Values are mean ± SEM 
with n = 3. For 4A–4C, *P < 0.05, **P < 0.01, ***P < 0.001 compared with 2.5% polymer concentration for each polymer type. 
D
P < 0.05, 
DD
P < 0.01, 
DDD
P < 0.001 compared with 
5% polymer concentration for each polymer type. 
 
 
50 mA with constant voltage modes of 60 V and 120 V during 
stacking and running, respectively (Park et al., 1998). 
 
2.6. In vivo studies 
 
2.6.1. Experimental animals 
Young (8-week-old) male National Institutes of Health Swiss 
mice (Harlan, UK) were age matched, divided into three groups and 
housed individually in an air-conditioned room at 22 ± 2 o C with a 
12:12 h light–dark cycle (08:00–20:00) with access to water and 
food ad libitum. To induce type I diabetes, weight-matched mice 
received a single intraperitoneal injection of streptozotocin (STZ, 
150 mg kg-1) dissolved in phosphate buffer (pH 7.4). For induction 
of type II diabetes, mice were placed on a special high-fat diet 
containing 45% kcal from fat, 20% kcal from protein and 35% kcal 
from carbohydrate (total  energy 19.5 kJ g-1, Dietex  International 
Ltd., Witham, UK) for 12 weeks prior to the experiment. Mice with 
fasting glucose level >8 mmol l-1 at 72 h post-STZ administration 
were considered diabetic and included in the study. Moreover, 
animals fed a high fat diet showed clearly manifested features of 
obesity-diabetes prior to the commencement of the study. All 
animal experiments were carried out in accordance with the UK 
Animals (Scientiﬁc Procedures) Act of 1986 and the University of 
Ulster’s Animal Ethics Committee guidelines. 
 
2.6.2. In vivo sensitivity of insulin formulations 
Glycaemic responses of Swiss TO mice, with diet-induced 
obesity-diabetes, to intraperitoneal injection of the test insulin 
formulation were assessed. Overnight fasted mice were given 
saline (control) or 25 U kg-1 body weight (ip) of free insulin and 
insulin-loaded NP suspended in sterile PBS. Blood glucose was 
measured using an Ascencia counter meter (Bayer Healthcare, UK) 
from blood samples collected by tail vein puncture prior to and at 
30, 60, 120 and 180 min post insulin injection (Trinder, 1969). 
 
2.6.3. In vivo bioactivity of insulin formulation 
Four groups (n = 5) of diabetic mice were used for this study. 
Insulin-loaded NP and free insulin were suspended in sterile PBS 
and injected subcutaneously into the neck region at a dose of 
25 U kg-1 body weight. The two control groups comprised mice 
treated with saline or blank NP. Blood samples were withdrawn by 
tail vein puncture prior to injection and at predetermined time 
points thereafter. Blood glucose and insulin were measured as 
described previously (Flatt and Bailey, 1981). All blood samples 
were withdrawn in the morning following an overnight fast, except 
for samples taken at 0.5, 6 and 12 h after dosing. Blood glucose 
concentrations were determined by the glucose oxidase method 
(Trinder, 1969), while serum insulin was measured by radioim- 
munoassay (Flatt and Bailey, 1981). 
 
2.7. Statistical analysis 
 
Results are presented as mean ± standard error mean (SEM). 
Particle size, zeta potential, entrapment efﬁciency and values of in 
vitro release proﬁles were treated statistically using one-way 
analysis of variance (ANOVA) followed by Tukey’s post hoc test. For 
in vivo studies, values were compared using one-way ANOVA 
followed by Student-Newman-Keuls post hoc test. Area under the 
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Fig. 5. Effects of internal water volume on insulin nanoparticle size (A), zeta potential (B), encapsulation efﬁciency (C) and insulin in vitro release (D). Values are mean ± SEM 
with n = 3. For 5A–5C, *P < 0.05, **P < 0.01, ***P < 0.001 compared with 0.2 ml for each polymer type. 
D
P < 0.05, 
DD
P < 0.01, 
DDD
P < 0.001 compared with 0.5 ml for each 
polymer  type. 
 
 
curve (AUC) analysis was performed using the trapezoidal rule 
with baseline correction. P < 0.05 was considered statistically 
signiﬁcant. 
 
3. Results and discussion 
 
This study investigated the outcome of variation in four key 
formulation parameters, as illustrated in Table 1,  on the 
physicochemical characteristics of insulin-loaded NP. The polymer 
type and its concentration in the organic phase of the primary 
emulsion were investigated. The concentration of PVA in the 
continuous phase of the secondary emulsion was also examined, 
together with the volume of aqueous phase used to dissolve the 
insulin at the beginning of the procedure. Experimental responses, 
such as particle size, surface charge, morphology, encapsulation 
efﬁciency and in vitro release were determined. 
 
3.1. Effect of polymer type 
 
The physicochemical properties of three different formulations 
of insulin NP (F1, F4 and F7) (Table 1) made by varying the polymer 
type, are presented in Fig. 2. NP were characterised by a larger 
diameter relative to those prepared by other reported techniques, 
such as nanoprecipitation or the single emulsion methods (Mora- 
Huertas et al., 2010). However, All NP formulations showed low 
polydispersity index (PDI) ranging from 0.185 to 0.442. PLGA NP 
 
 
Table 2 
Physicochemical properties of optimised insulin NP. 
 
Formula ID Size(nm) PDI Zeta potential (mV) EE %a Burst release after 24 hb 
F20 231.50 ± 19.00 0.378 ± 0.52 -6.15 ± 2.70 90.98 ± 2.40 57.60 ± 2.40 
F22 304.00±16.40*** 0.234 ± 0.34* -6.13 ± 1.40 95.50 ± 0.90* 44.63 ± 2.50** 
F23 379.75 ± 13.70***DDD 0.397 ± 0.47DD -5.23 ± 1.50 96.85 ± 1.40* 42.49 ± 4.00** 
DD
P < 0.01. 
DDD
P < 0.001 compared with F22. 
*   
P < 0.05. 
**  
P < 0.01. 
***   
P < 0.001 compared with F20. 
a 
Encapsulation efﬁciency. 
b 
Expressed as a % of total theoretical release. 
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Fig. 6. Scanning electron micrographs of F22 after formulation (A) and after 7 days of in vitro release (B). 
 
 
 
(F1) was signiﬁcantly bigger in size (P value < 0.05) than those 
prepared from 5% PEG–PLGA (F4) and 10% PEG–PLGA (F7) diblock 
copolymers (Fig. 2A). Increasing the percentage of PEG in the 
polymer and using a lower molecular weight (compared to the 
PLGA polymer) caused a decrease in diameter, a ﬁnding explained 
by copolymeric PEG decreasing polymer association during NP 
formation (Beletsi et al., 2005). F1 exhibited negative zeta potential 
values  of  -20.9 mV,  which  was  signiﬁcantly  higher  (P  value 
< 0.001) than that of the PEGylated PLGA (F4  and  F7)  types 
(Fig. 2B). PEG is known to be amphiphilic, decreasing measurable 
zeta potential by shielding the native PLGA surface charge (Mora- 
Huertas et al., 2010). Insulin loading and encapsulation efﬁciency 
were signiﬁcantly increased (P value < 0.01) in PEGylated PLGA NP 
(F4 and F7) compared to PLGA (F1). Increasing the % PEG in the 
polymer resulted in further signiﬁcant increases (P value < 0.05). 
The amphiphilic nature of PEG–PLGA facilitates micelle formation 
in the primary emulsion and enhances the encapsulation of 
hydrophilic molecules (Locatelli and Comes Franchini, 2012). The 
higher encapsulation efﬁciency seen with 10% PEGylated PLGA NP 
(Fig. 2C) can be explained by considering its lower solubility in 
DCM compared to both PLGA and 5% PEGylated PLGA. Unwanted 
diffusion of hydrophilic drugs into the continuous phase of the 
secondary emulsion is most likely to occur during the polymer 
solidiﬁcation stage, which is normally during the ﬁrst 10 min of 
emulsiﬁcation. PEGylated polymers with low solubility in DCM 
will solidify quicker during this crucial phase and give rise to 
higher encapsulation efﬁciencies (Mehta et al., 1996). In vitro 
release proﬁles for F1, F4 and F7 showed evidence of a burst 
release, with the rate signiﬁcantly higher from F4 and F7, which 
released approximately 66% and 72% of insulin, respectively, 
within the ﬁrst 24 h, when compared to 38% of insulin released 
from the F1 (Fig. 2D). Burst release phenomenon is attributed to 
drug attached on or close to the surface of the NP (Essa et al., 2010). 
These results suggest that there is a higher amount of insulin 
attached to the PEGylated NP surface compared to PLGA NP 
because of presence of PEG chains. Moreover, PEG chains are 
 
hydrophilic and can be easily hydrated in an aqueous release 
medium and this facilitates water permeation into the NP matrix, 
allowing insulin to be released. A higher content of PEG accelerated 
surface dissolution because water was taken up more readily when 
compared with the PLGA NP (Locatelli and Comes Franchini, 2012). 
 
 
 
 
 
 
Fig. 7. SDS PAGE images of free insulin and an insulin sample released from NP 
formulation (F22) after 7 days of in vitro analysis. Molecular weight markers (lane 
1), Free insulin dispersed in PBS (lane 2), Insulin released from F22 (lane 3). 
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Fig. 8. Insulin sensitivity in Swiss TO mice with diet-induced obesity-diabetes 
expressed as line graph (A) and area under the curve (B). Values are mean ± SEM 
with n = 4. Plasma glucose was measured prior to and at 30, 60, 120 and 180 min 
after intraperitoneal injection of  saline,  insulin  or  nanoparticle  encapsulated 
insulin. **P < 0.01 compared with the saline group. Insulin NP is F22. 
 
 
 
3.2. Effect of PVA concentration in the external aqueous phase 
 
PVA is a commonplace stabiliser utilised in the formulation of 
PLGA NP, producing desirable and tightly dispersed size distribu- 
tions (Sahoo et al., 2002). PVA concentration in the external 
aqueous phase of the secondary emulsion has been shown to 
control NP size (Fig. 3A), which was a ﬁnding also observed in this 
work (Jeffery et al., 1993). This was attributed to increased viscosity 
of the continuous phase and enhanced emulsion stability during 
homogenisation. Increasing the emulsion stability prevented 
premature emulsion coalescence and maintained a  small  mean 
and tight size  distribution  following  NP  maturation  (Zambaux 
et al., 1998). Increasing the PVA concentration resulted in a 
signiﬁcant decrease in zeta potential (P value < 0.05) across  all 
three polymer types, as seen in Fig. 3B. This drop is explained by 
coating of the NP with a residual PVA layer, thereby attenuating 
surface charge. Moreover, a signiﬁcant increase in insulin loading 
(P value < 0.05) and encapsulation efﬁciency were obtained by 
increasing PVA concentration (Fig. 3C). This is explained on the 
basis of increased viscosity of the continuous phase in the 
secondary emulsion and interfacial effects, shown elsewhere to 
resist insulin diffusion out of polymer-rich phases, leading to 
higher protein loadings (Zambaux et al., 1998). The release proﬁles 
of different insulin-loaded NP prepared with 1.25%, 2.5%, and 5% 
PVA are shown in Fig. 3D. The release of F1, F4 and F7 prepared with 
 
1.25% PVA in the external phase showed a signiﬁcantly lower initial 
burst release (P value < 0.05) compared to those for F3, F6 and 
F9 prepared with 5% PVA. If the burst release is considered to be 
diffusion primarily from peripheral drug, then any parameter that 
reduces mean NP size, such as PVA concentration, is expected to 
increase surface area and the rate of release. The results in this 
work and the ﬁndings of others support that contention (Fude 
et al., 2005). 
 
3.3. Effect of polymer concentration 
 
The effect of polymer concentrations on the physicochemical 
properties of insulin-loaded NP is shown in Fig. 4. Three different 
formulations for each type of polymer were used (F1, F10 and F11), 
(F4, F12 and F13) and (F7, F14 and F15) (Table 1). NP size was 
increased signiﬁcantly (P value < 0.01) by increasing polymer 
concentration in DCM from 2.5% w/v to 7.5% w/v (Fig. 4A). This 
arises due to increased viscosity of the organic phase and the 
formation of larger dispersed droplets in the secondary emulsion 
under conditions of constant shear (Fude et al., 2005; Lamprecht 
et al., 2000). However, increasing the polymer concentration from 
2.5% w/v to 5% w/v did not increase PLGA NP size signiﬁcantly (F1 
and F10) (P value > 0.05), but did when 5% PEG–PLGA and 10% PEG– 
PLGA were used (P value < 0.05) at these intermediate levels (F4, 
F12 and F7, F14, respectively). It was also shown that increasing the 
polymer concentration had no effect on the surface  charge  (P 
value > 0.05) (Fig. 4B). Signiﬁcant increases in insulin encapsula- 
tion efﬁciency were demonstrated by increasing the different 
polymer concentration from 2.5% w/v (F1, F4 and F7) to 7.5% w/v 
(F11, F13 and F15) (Fig. 4C) but in a similar pattern observed with 
NP size, increases of 2.5% w/v to 5% w/v PLGA did not enhance 
insulin loading (F1 and F10). These patterns of enhanced 
entrapment efﬁciency are attributed to  the  higher  viscosity  of 
the DCM phase as more polymer amount is present and the 
ensuing larger size of the primary emulsion droplets. Furthermore, 
higher polymer concentrations give rise to more rapid polymer 
deposition as the DCM is removed from the system, which is 
expected to retard any unwanted insulin dissolution into the 
continuous phase of the secondary emulsion (Rafati et al., 1997). 
The inﬂuence of different polymer concentrations on the 
release proﬁle is shown in Fig. 4D. The initial burst release was 
decreased by increasing the polymers concentrations. PLGA NP 
(F11) showed the lowest burst effect of 23.6% of insulin released in 
24 h. Similar patterns were observed after increasing the polymer 
concentration of the PEGylated variants, A decrease in burst release 
from 66% to 42% and from 72% to 52% was observed with 5% PEG– 
PLGA NP and 10% PEG–PLGA NP, respectively, The decrease in initial 
release is explained by rapid solidiﬁcation of the polymer-rich 
phase due to higher polymer concentrations in the primary 
emulsion. This process leads to a dense matrix that offers low 
permeability to entrapped protein and a more tortuous structure 
because of the chain entanglement (Yang et al., 2001). 
 
3.4. Effect of internal aqueous phase volume 
 
The inﬂuence of the internal aqueous phase volume on the 
physicochemical characteristics is shown in Fig. 5. In this work, the 
volume of organic phase was held constant and so increases in the 
internal aqueous phase volume would lead to an increase in the 
mean diameter of the dispersed phase in the secondary emulsion 
(Fig. 5A) (Crotts and Park, 1995). Variation in internal aqueous 
phase volume did not affect zeta potential (Fig. 5B). However, 
signiﬁcant effects (P value < 0.05) were observed on the encapsu- 
lation efﬁciency (Fig. 5C). A small internal phase volume of 0.2 ml 
enhanced loading, although this ﬁnding is not always observed 
(Crotts and Park, 1995). The results in this work could be explained 
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Fig. 9. Effects of insulin and insulin NP on blood glucose concentrations in 
streptozotocin-induced diabetic Swiss TO mice expressed as line graph (A and B) 
and area under the curve (C). Blood glucose concentrations were measured prior to 
and after intraperitoneal injection of insulin or insulin NP (25 U/kg bw) in 
streptozotocin-induced  mice  for  144 h.  Values  are  mean ± SEM  for  6  mice. 
*P < 0.05, **P < 0.01compared to saline. 
D
P < 0.05 compared to free insulin. Insulin 
NP is F22. 
 
by the effectiveness of the deposited polymer network during DCM 
evaporation from the secondary emulsion. Increases in the internal 
aqueous phase whilst the organic phase remains constant means 
that the thickness of a nascent polymer ﬁlm is thinner and is less 
effective in preventing premature leakage of insulin and other 
potential payloads into the continuous phase of the secondary 
emulsion (Li, 1999). Insulin release proﬁles are shown in Fig. 5D 
with the initial burst release from NP with the lowest internal 
water volume (F16, F18 and F20) (Table 1) signiﬁcantly lower (P 
value < 0.05) than those of higher internal phase volumes (F17, 
F19 and F21). It has been shown that increases in internal phase 
volume produce NP with discernible surface pores, leading to a 
particulate matrix that is receptive to release medium ingress and 
payload dissolution (Crotts and Park, 1995). The data in Table 2 
shows the formulations considered to be optimised for further 
investigation. These data detail NP with low mean size and high 
encapsulation efﬁciency. Increasing the polymer concentration 
(10% PEG–PLGA) to 5% and 7.5% w/v, in order to decrease the initial 
 
burst release, was achieved in F22 and F23. F22 was used as the 
optimised formulation for further in vitro and in vivo characterisa- 
tion based on its lower NP size and lower PDI compared to 
F23 besides higher encapsulation efﬁciency and lower burst 
release compared to F20. 
 
3.5. Scanning electron microscopy 
 
Fig. 6A shows an SEM image of F22. The insulin NP had a 
spherical appearance with a narrow size distribution. The nano- 
particles’ surface is free from pores. Fig. 6B was obtained after 
7 days of release and show insulin-loaded NP displaying poor 
retention of spherical shape with increased evidence of erosion. 
The high content of PEG in the block polymer resulted in the 
formation of large pores and voids, which subsequently favoured 
insulin diffusion from the NP (Kang and Singh, 2001). This is 
consistent with release data showing approximately 90% of insulin 
released in the ﬁrst 4 days of in vitro analysis. 
 
3.6. In vitro stability and in vivo insulin sensitivity 
 
Encapsulation of insulin in polymer constructs is problematic 
for a number of reasons. Its surface activity leads to adsorption at 
interfaces, resulting in instability caused by unfolding, inactivation 
or irreversible aggregation. Furthermore, high rates of shear, often 
associated with emulsiﬁcation based techniques, affect the three- 
dimensional structure of insulin, maintenance of which is essential 
for therapeutic activity (Manoharan and Singh, 2009; Perez et al., 
2002). Formation of insulin loaded NP by a double emulsion 
technique uses either sonication or homogenisation as a source of 
high shear agitation (Blum and Saltzman, 2008). In the current 
work, homogenisation was used to create both primary and 
secondary emulsions, due to the following reasons. It is an effective 
means to form (w/o/w) double emulsion, resulting in NP with high 
reproducibility, particle size uniformity and low polydispersity (Li 
et al., 2008). Additionally, there is evidence that microparticles 
prepared using homogenisation gave higher encapsulation efﬁ- 
ciencies with desirable linear release proﬁles of hydrophilic drugs, 
such as DNA, when compared to the same particles fabricated 
using sonication, which resulted in a lower DNA encapsulation 
efﬁciency and a higher burst release (Blum and Saltzman, 2008). 
Given its susceptibility to instability, insulin aggregation during 
formulation and after in-vitro release were analysed as part of this 
study. Analysis using SDS PAGE, as shown in Fig. 7, shows the 
insulin band of the naked and encapsulated insulin. Entrapped 
insulin did not suffer signiﬁcant aggregation following formulation 
and during in vitro release. It could be argued that the surface 
activity of PEGylated PLGA during formation of the primary 
emulsion impedes insulin adsorption at the DCM-water interface 
and helps prevent possible aggregation. To investigate conforma- 
tional stability and sensitivity of insulin encapsulated in PEG– 
PLGA, Swiss TO mice with diet-induced obesity-diabetes (type II) 
were used. This diabetic animal model is closely aligned to diabetic 
obesity found increasingly in humans consuming high-fat and 
energy-rich diets (McClean et al., 2007). The high-fat diet resulted 
in glucose intolerance and impaired insulin sensitivity in animals 
used in this study (Bailey et al., 1986; Flatt et al., 1990). Results in 
Fig. 8(A and B) showed that the optimised insulin NP (F22) 
signiﬁcantly decreased plasma glucose level (P value < 0.01) 
directly after intraperitoneal injection, compared to the saline 
group. It showed similar hypoglycaemic control compared to free 
insulin at the same dose of 25 U kg-1  during the ﬁrst three hours 
after injection. However, the decrease in blood glucose  level 
occurred after treatment with the free insulin was higher than 
insulin released from the NP due to only initial burst release during 
the ﬁrst three hours. These results demonstrated the sensitivity of 
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Fig. 10. Effects of insulin and insulin NP on plasma insulin concentrations in 
streptozotocin-induced diabetic Swiss TO mice expressed as line graph (A) and area 
under the curve (B). Plasma insulin concentrations were measured prior to and after 
intraperitoneal injection of insulin or insulin NP (25U/kg bw) in streptozotocin- 
induced mice for 144 h. Values are mean ± SEM for 6 mice. *P < 0.05, **P < 0.01, 
***P < 0.001 compared with free insulin. Insulin NP is F22. 
 
the encapsulated insulin, which in turn validated its conforma- 
tional stability. 
 
3.7. In vivo insulin bioactivity 
 
The effect of a single subcutaneous administration of insulin NP 
(F22) on blood glucose level of streptozotocin-induced type I 
diabetic mice is shown in Fig. 9A–C. Streptozotocin uptake via the 
cell membrane GLUT2 glucose transporter, causing DNA alkylation 
and eventual b cell death, mimics autoimmune T-lymphocytes- 
related insulitis that characterizes type 1 diabetes in humans 
(Rossini et al., 1977; Deeds et al., 2011). The appropriateness of 
chemically-induced diabetes in investigations involving drug 
testing or in therapies working via non-beta cell dependent 
pathways, such as new insulin formulation tested in this study, has 
been widely reported (Jederstrom et al., 2005; Sheshala et al., 
2009). 
Following subcutaneous injection of free insulin (25 U kg-1), 
blood glucose level decreased signiﬁcantly by 58 % (P value < 0.05) 
after 30 min. The plasma glucose level decreased further to its 
lowest level of 21% of the original value, 3 h after administration. 
This effect was maintained up to 3 h, then glycaemia increased 
sharply and plasma glucose values started to return to its control 
level before the injection. The glycaemic proﬁle of the same dose of 
insulin NP showed only a 12% reduction in blood glucose levels 
after the ﬁrst 30 min. After 3 h, the maximum decrease in plasma 
glucose was similar to what was observed for free insulin. A 
signiﬁcant difference between the two groups was noted after 6 h 
post injection with insulin NP maintaining a signiﬁcant decrease in 
blood glucose level (P value < 0.05) for up to 144 h after the 
injection. Beyond this period, no signiﬁcant difference  was 
observed in blood glucose level in mice injected with free insulin 
 
or insulin NP (P value > 0.05). During the ﬁrst 6 days following 
injection, the blood glucose level of mice treated with F22 did not 
return to the original level compared with control mice or mice 
injected with free insulin. These observations indicate that the NP 
had the ability to hold and release insulin in a sustained manner. 
Plasma insulin levels in mice injected with saline, free insulin or 
encapsulated insulin (Fig. 10A) revealed a mean peak for serum 
insulin concentration (Cmax) of 16 ng ml
-1 achieved after 30 min of 
injection in mice treated with free insulin. This was followed by a 
97% (P < 0.001) decreased after 3 h. However, mice injected with 
encapsulated insulin showed a peak insulin concentration 2 h after 
injection followed by a 79% decrease in serum insulin level after 
24 h. The therapeutic insulin level in the latter mice remained 
between 3.36 and 0.6 ng ml-1 for up to 6 days post injection. 
Moreover, a signiﬁcant difference in blood glucose level  (P 
value < 0.001) was observed in the insulin NP group for up to 
144 h (Fig. 10B). It was clear that insulin NP prolonged the 
hypoglycaemic effect of the free insulin from 3 h to 6 days. 
Parenteral administration of PEG–PLGA insulin NP resulted in a 
depot injection at the site of administration that could release the 
encapsulated insulin by gradual diffusion across the polymeric 
matrix. 
Though oral delivery of insulin remains a challenge due to its 
limited oral absorption resulting from rapid degradation by 
proteolytic enzymes in the gastrointestinal tract and inadequate 
transport across the intestinal epithelium, encapsulation of insulin 
into nanoparticles has been identiﬁed as a promising means of 
facilitating oral insulin delivery due to its ability to promote greater 
insulin transport across the intestinal mucosa (Fonte et al., 2013). 
While it is not yet clear if the encapsulation reported in this study 
prevented proteolytic degradation of insulin, our data highlight a 
sizeable difference between the slower insulin release kinetics in 
vivo compared to in vitro results. The major reason for the slower in 
vivo kinetics might be attributed to lower water availability in the 
body tissues compared with the in vitro conditions, in which 
insulin NP are incubated in aqueous release media at 37 o C with 
continuous shaking (Blanco-Prieto et al., 2004). Based on this, the 
tissue micro-environment surrounding the insulin NP will retard in 
vivo release. 
 
 
4. Conclusions 
 
Optimising the entrapment efﬁciency and release kinetics of 
insulin using a modiﬁed double emulsion solvent evaporation 
technique utilising homogenisation while preserving stability and 
biological activity during fabrication and release can be achieved 
through adjustment of process variables. Of particular impor- 
tance is the ratio of the internal aqueous phase to the volume of 
organic solvent that comprising the primary emulsion. Insulin- 
loaded 10% PEGylated PLGA NP with improved physicochemical 
properties was superior to conventional PLGA NP based on in vitro 
characterisation. The amphiphilic nature of the PLGA–PEG block 
copolymers allow for better dispersion of the insulin-containing 
aqueous phase  into the  double emulsion, thus  improving 
encapsulation efﬁciency. Moreover, PEG residues in the matrix 
preserve insulin stability during manufacture, minimising aggre- 
gation and inactivation, as conﬁrmed by in vivo results. A single 
weekly injection of PEGylated insulin NP sustained the delivery of 
basal insulin requirement in streptozotocin-induced mice. 
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